Clinical trials: Hemosiderosis
Hereditary Hemochromatosis
Erythrocytapheresis Versus Phlebotomy as Maintenance Therapy in Hereditary Hemochromatosis (HH) Patients
Hereditary hemochromatosis (HH) is a genetic disorder of iron metabolism, resulting in excessive iron overload. Phlebotomy is currently the standard therapy.
- Trial name
- NCT01398644
- Testing
- Phlebotomy and erythrocytapheresis
- Where
- Netherlands
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Sanquin Research & Blood Bank Divisions
Hemochromatoses, Genetic
Transferrin Saturation and Asthenia in Hemochromatosis
Observational study.
- Trial name
- HEMOSAT (NCT03356548)
- Where
- France
- Volunteers
- 260 people
- Sponsor
- Rennes University Hospital
Blood Disease, Hemochromatosis
Statistical Basis for Hemochromatosis Screening
To determine optimal values for transferrin saturation for use in population screening for hereditary hemochromatosis.
- Trial name
- NCT00005559
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Idiopathic Pulmonary Hemosiderosis, Leflunomide
Leflunomide for Idiopathic Pulmonary Hemosiderosis in Children
The goal of this clinical trial is to compare Leflunomide in Idiopathic pulmonary hemosiderosis. The main questions it aims to answer are: The efficacy and safety of Leflunomide in Idiopathic pulmonary hemosiderosis The mechanism…
- Trial name
- Lef for IPH (NCT05937191)
- Testing
- Leflunomide, Steroid Drug
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Iron Overload, Excessive Body Iron Burden
Massive Iron Deposit Assessment
Iron overload is a severe complication of multiple blood transfusions. As the body has no physiologic mechanism for clearing iron, repeated transfusions cause iron accumulation in organs and lead to iron toxicity.
- Trial name
- NCT01572922
- Testing
- R2*-UTE, R2*-GRE, Liver biopsy
- Where
- United States
- Volunteers
- 142 people
- Sponsor
- St. Jude Children's Research Hospital
Hemochromatosis, Myelodysplastic Syndromes
Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome
Hypothesis: Deferasirox can be used as a therapeutic agent to deplete the liver, heart and bone marrow of excess iron in patients with iron overload caused by myelodysplastic syndrome (MDS) and hemochromatosis (HC.
- Trial name
- DefeHEMY (NCT01892644)
- Testing
- Deferasirox, Venesection
- Where
- Norway
- Volunteers
- healthy volunteers welcome
- Sponsor
- Haukeland University Hospital
Porphyria Cutanea Tarda
Risk Factors of Porphyria Cutanea Tarda (PCT)
Comparison of patients with documented PCT and HCV infection, documented PCT without HCV, HCV infection without PCT and controls without HCV or PCT.
- Trial name
- NCT00213772
- Volunteers
- 280 people
- Sponsor
- University Hospital, Strasbourg, France
Genetic Hemochromatosis
Bone Status on Patients With Genetic Hemochromatosis: a 3 Years Descriptive and Evolutionary Study
The purpose of this study is to describe bone status on patients with genetic hemochromatosis, at diagnostic time and his evolution under treatment.
- Trial name
- FEROS (NCT01556360)
- Where
- 6 sites in France
- Volunteers
- 100 people
- Sponsor
- Rennes University Hospital
Hereditary Hemochromatosis
Clinical Management of Hereditary Hemochromatosis: Phlebotomy vs. Erythrocytoapheresis
The purpose of study is to determine the best and durable choice of treatment between phlebotomy and eritrocytoapheresis in the medium- and long-term clinical management of HH
- Trial name
- NCT00440986
- Testing
- Eritrocytoapheresis
- Where
- Italy
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- San Filippo Neri General Hospital
Hemochromatosis, Iron Overload
Iron Overload in African Americans
Iron overload (hemochromatosis) is a condition which causes the intestines to take too much iron into the body from food or pills. The extra iron can build up in the liver, heart, joints, pancreas, sex organs, and other organs.
- Trial name
- NCT00001455
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Transfusional Iron Overload, Transfusional Hemosiderosis
Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload
This is a clinical research study in patients who have iron overload in the heart due to chronic blood transfusions. The study will have 2 treatment groups and will compare the safety and efficacy of chelation therapy with a…
- Trial name
- CORDELIA (NCT00600938)
- Testing
- Core Study: Deferasirox, Core Study: Deferoxamine, Extension: deferoxamine to deferasirox
- Where
- 21 sites in Canada, China and 9 more
- Volunteers
- 197 people
- Sponsor
- Novartis Pharmaceuticals
Compensated Cirrhosis
Screening of Hepatocellular Carcinoma in Patients With Compensated Cirrhosis
Liver carcinoma is becoming the main complication of cirrhosis. Treatment of symptomatic or large tumors is disappointing. Regular ultrasonographic screening of small (curable) tumors is currently recommended, but the best…
- Trial name
- NCT00190385
- Testing
- Ultrasonographic screening
- Where
- France
- Volunteers
- 1,200 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Myelodysplastic Syndromes, Hemosiderosis
Safety, Tolerability, and Efficacy of Deferasirox in MDS
Open label, single arm study on Deferasirox treatment in MDS patients with chronic transfusional hemosiderosis. Patients receive daily oral dosis of Deferasirox in order to eliminate the quantity of iron administered during…
- Trial name
- NCT00469560
- Testing
- Deferasirox
- Where
- 17 sites in Italy
- Volunteers
- 158 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Hemosiderosis
Pharmacogenetic Study in Patients Received Iron Chelating Agent
To investigate effect of genetic variations on the toxicities and find optimal target population, the investigators planned to analyze the genetic polymorphisms of UDP-glucuronosyltransferase.
- Trial name
- NCT01623895
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Seoul National University Hospital
Iron Overload, Hemochromatosis
Confounder-Corrected Quantitative MRI Biomarker of Hepatic Iron Content
The purpose of this multi-site research is to validate a rapid magnetic resonance based confounder-corrected R-2 mapping method as a quantitative imaging biomarker of liver iron concentrations.
- Conditions
- Iron Overload, Hemochromatosis, Hemosiderosis
- Trial name
- NCT02025543
- Testing
- MRI
- Where
- 4 sites in United States
- Volunteers
- 207 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Iron Overload
Iron Overload in Stem Cell Transplant Recipients
The goal of this study is to examine the impact of iron overload in patients undergoing a bone marrow transplant. We believe that the iron status in these patients is associated with complications for transplant survivors.
- Trial name
- NCT00806715
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Boston Children's Hospital
Myocardial Iron Overload, HFE-Associated Hereditary Hemochromatosis
Estimation of Myocardial Iron Overload by 3 Tesla MRI in HFE Hereditary Haemochromatosis
Hereditary haemochromatosis (HHC) is a frequent disease in Brittany (5 to 7‰), responsible first for biological disorder in blood iron parameters and minor clinical disorders, before evolving to potential life-threatening…
- Trial name
- HEMOCOEUR (NCT02099214)
- Testing
- 3Tesla cardiac MRI, Electrocardiogram (EKG), Iron and cardiac markers
- Where
- France
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Rennes University Hospital
Hemochromatosis
Treatment of Hemochromatosis
This study will evaluate the effectiveness of a test called MCV in guiding phlebotomy (blood drawing) therapy in patients with hemochromatosis an inherited disorder that causes too much iron to be absorbed by the intestine.
- Trial name
- NCT00007150
- Testing
- Phlebotomy
- Where
- United States
- Volunteers
- 622 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Iron Overload, Thalassemia Major
"Iron Overload and Endocrinological Diseases"
Patients with hemochromatosis or Thalassemia develop progressive tissue and organs damages secondary to iron overload. Iron overload can result both from transfusional hemosiderosis and excess gastrointestinal iron absorption.
- Conditions
- Iron Overload, Thalassemia Major, Thalassemia Intermedia, Hemochromatosis
- Trial name
- NCT06137079
- Where
- Italy
- Volunteers
- 62 people
- Sponsor
- Azienda Ospedaliero-Universitaria di Modena
Iron Overload
Efficacy and Safety of Oral Deferasirox (20 mg/kg/d) in Pts 3 to 6 Months After Allogeneic Hematopoietic Cell Transplantation Who Present With Iron Overload
The purpose of this study is to investigate the effects of iron chelation using deferasirox in patients who show signs of iron overload after an allogeneic stem cell transplantation The iron overload must be due to blood…
- Trial name
- NCT00654589
- Testing
- Deferasirox
- Where
- Germany
- Volunteers
- 75 people
- Sponsor
- Novartis Pharmaceuticals